Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: Cancer Gene Ther. 2015 Jan 30;22(3):154–162. doi: 10.1038/cgt.2015.2

Fig. 1. Vaccination of naïve FVB/N mice with VVneu induces a systemic HER2-specific Th1 response.

Fig. 1

(a) Female FVB/N mice were injected twice, two weeks apart, with VVneu + VVGMCSF (either s.c. or i.m.f.), VVBGal + VVGMCSF (i.m.f.), or vehicle (i.m.f.). Two weeks after the second and final vaccination, spleens were restimulated with irradiated splenocytes from naïve female FVB/N mice that had been pulsed with immunodominant RNEU420-429 peptide. (b) NBT1 tumor-specific systemic (spleen) CTL activity against NBT1 target cells after restimulation. Differences of both s.c. and i.m.f. VVneu + VVGMCSF groups compared to controls were significant (** P < 0.01, * P < 0.05). Results are representative of 3 independent experiments.